Telomir Pharmaceuticals (TELO) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Telomir Pharmaceuticals, Inc.'s (NASDAQ:TELO) Biggest Owners Are Retail Investors Who Got Richer After Stock Soared 13% Last Week
Yahoo FinanceJan 16 09:51 ET
Renovaro Names Nathen Fuentes as CFO
MT NewswiresJan 7 10:02 ET
Telomir Pharmaceuticals Shares Are Trading Higher After the Company Announced Potentially Groundbreaking Findings From a Preclinical Progeria Lifespan Study.
BenzingaJan 7 08:49 ET
Telomir Pharmaceuticals Confirms Lifespan Restoration and Normalization of Accelerated Aging in Preclinical Model of Progeria (A Rare Genetic Disorder Causing Rapid Aging)
AccesswireJan 7 08:00 ET
Express News | Telomir Pharmaceuticals: Confirms Lifespan Restoration and Normalization of Accelerated Aging in Preclinical Model of Progeria
ReutersJan 7 07:33 ET
Express News | Telomir Pharmaceuticals Inc - to Submit Ind & Inad Application by Q4 2025, With Clinical Trials Planned for 2026
ReutersDec 23, 2024 07:04 ET

Comments

Teddy123

Jan 13 06:16

Recap: Late run perhaps?

$Telomir Pharmaceuticals (TELO.US)$
From an investment perspective, these preclinical results substantially enhance TELO's value proposition. With a market cap of just $135M, the company appears undervalued given the broad therapeutic potential of Telomir-1. The addressable market spans rare diseases like progeria (~400 patients globally) to massive markets like Type 2 diabetes, creating a compelling risk-reward profile.
The metal ion regulation mechanism is particularly...

4

Jaguar8

Jan 7 20:00

⚫️ Watchlist JANUARY 8,2025, Wednesday NFA

NOTE!
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release
7. Remember, some stocks may get pumped WITHOUT any catalyst
8. NEVER be a blind follower.
LASTLY, If y...

54

34

12

Teddy123

Jan 7 10:12

Biotech investment analysis

$Telomir Pharmaceuticals (TELO.US)$
From an investment perspective, these preclinical results substantially enhance TELO's value proposition. With a market cap of just $135M, the company appears undervalued given the broad therapeutic potential of Telomir-1. The addressable market spans rare diseases like progeria (~400 patients globally) to massive markets like Type 2 diabetes, creating a compelling risk-reward profile.
The metal ion regulation mechanism is particular...

3

Teddy123

Jan 7 07:39

Positive medical research analysis

$Telomir Pharmaceuticals (TELO.US)$
The preclinical study results for Telomir-1 represent a significant scientific breakthrough in addressing accelerated aging conditions. The restoration of lifespan in wrn-1-mutated C. elegans to normal levels demonstrates robust proof-of-concept for Telomir-1's mechanism of action. The normalization of physiological parameters like movement velocity provides tangible evidence of improved healthspan, not just lifespan.
The comp...

Jaguar8

Jan 7 07:04

NEWS

$Telomir Pharmaceuticals (TELO.US)$
Telomir Pharmaceuticals Confirms Lifespan Restoration and Normalization of Accelerated Aging in Preclinical Model of Progeria (A Rare Genetic Disorder Causing Rapid Aging)
Tuesday, 7th January at 8:00 am
MIAMI, FL / ACCESSWIRE / January 7, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) ("Telomir"), an emerging leader in age-reversal science focused on treating the root causes of diseases rather than just their symptoms, announced today potentially grou...

TELO Telomir Pharmaceuticals

Trade Overview

Capital Trend

News

Comments

Trending Stocks